Published in Health Aff (Millwood) on March 18, 2008
Access, quality, and costs of care at physician owned hospitals in the United States: observational study. BMJ (2015) 1.40
Environmental Factors Contributing to Wrongdoing in Medicine: A Criterion-Based Review of Studies and Cases. Ethics Behav (2011) 1.01
A comparison of ambulatory perioperative times in hospitals and freestanding centers. Am J Surg (2012) 0.84
Organizational boundaries of medical practice: the case of physician ownership of ancillary services. Health Econ Rev (2012) 0.81
Ambulatory Surgery Centers and Their Intended Effects on Outpatient Surgery. Health Serv Res (2015) 0.75
Timing of Dialysis Initiation-Do Health Care Setting or Provider Incentives Matter? Clin J Am Soc Nephrol (2015) 0.75
Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm (2003) 3.34
Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care (2003) 2.33
Physicians' experiences using commercial e-prescribing systems. Health Aff (Millwood) (2007) 2.20
Costs of necrotizing enterocolitis and cost-effectiveness of exclusively human milk-based products in feeding extremely premature infants. Breastfeed Med (2011) 2.12
Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis (2004) 1.65
Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure. Cardiovasc Drugs Ther (2004) 1.46
Where's the value in health care? Value Health (2006) 1.45
Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II. Value Health (2009) 1.43
An update on safety-net hospitals: coping with the late 1990s and early 2000s. Health Aff (Millwood) (2005) 1.41
Developing a pathway for high-value, patient-centered total joint arthroplasty. Clin Orthop Relat Res (2013) 1.39
Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. J Manag Care Pharm (2006) 1.26
A survey of hospital quality improvement activities. Med Care Res Rev (2008) 1.25
Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999-2004. Curr Med Res Opin (2009) 1.21
The influence of health policy and market factors on the hospital safety net. Health Serv Res (2006) 1.11
Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI. Value Health (2009) 1.11
Cost-effectiveness analysis of pharmaceutical care in a medicare drug benefit program. Value Health (2003) 1.09
Evaluating the cost-effectiveness of statins. J Manag Care Pharm (2004) 1.08
Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV. Value Health (2009) 0.98
Understanding the underlying drivers of inpatient cost growth: a literature review. Am J Manag Care (2003) 0.96
Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III. Value Health (2009) 0.96
Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report--Part V. Value Health (2009) 0.96
Employer-sponsored health insurance and prescription drug coverage for new retirees: dramatic declines in five years. Health Aff (Millwood) (2004) 0.92
Effects of ambulatory-care pharmacist consultation on mortality and hospitalization. Am J Manag Care (2003) 0.91
Generosity and adjusted premiums in job-based insurance: Hawaii is up, Wyoming is down. Health Aff (Millwood) (2006) 0.88
Exceptions to outpatient quality measures for coronary artery disease in electronic health records. Ann Intern Med (2011) 0.88
Long term healthcare costs of infants who survived neonatal necrotizing enterocolitis: a retrospective longitudinal study among infants enrolled in Texas Medicaid. BMC Pediatr (2013) 0.88
Antidepressant use in geriatric populations: the burden of side effects and interactions and their impact on adherence and costs. Am J Geriatr Psychiatry (2011) 0.87
The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. Neuro Oncol (2013) 0.87
Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity-score and instrumental variable methods to adjust for treatment-selection bias. Pharmacoepidemiol Drug Saf (2012) 0.85
Costs and benefits of male circumcision. JAMA Pediatr (2013) 0.85
Asthma costs and utilization in a managed care organization. J Allergy Clin Immunol (2008) 0.83
Medicare cost differences between nursing home patients admitted with and without dementia. Gerontologist (2005) 0.81
Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States. Pharmacoeconomics (2013) 0.80
The role of nursing home admission and dementia status on care for diabetes mellitus. J Am Geriatr Soc (2009) 0.79
Appropriate econometric methods for pharmacoeconometric studies of retrospective claims data: an introductory guide. J Manag Care Pharm (2005) 0.79
A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Opin Pharmacother (2007) 0.79
Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis. Expert Rev Pharmacoecon Outcomes Res (2015) 0.79
Cost-benefit analysis of in-hospital influenza vaccination of postpartum women. Obstet Gynecol (2012) 0.78
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer (2009) 0.78
Efficacy of bypassing agents in patients with hemophilia and inhibitors: a systematic review and meta-analysis. Clin Ther (2012) 0.77
Incremental expenditure of biologic disease modifying antirheumatic treatment using instrumental variables in panel data. Health Econ (2012) 0.76
Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine. CNS Drugs (2005) 0.76
Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia. PLoS One (2013) 0.76
Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S. Gen Dent (2010) 0.76
What is more valuable: fenofibrate patents or fenofibrate clinical outcomes? Arch Intern Med (2012) 0.75
Comparing patient access to pharmaceuticals in the UK and US. Appl Health Econ Health Policy (2006) 0.75
Effects of medicaid on clinical outcomes. N Engl J Med (2013) 0.75
Expensive conditions. Health Aff (Millwood) (2002) 0.75
A six-year study of diagnostic lower extremity imaging practice patterns and outcomes in the Veterans Affairs health care system. Int J Angiol (2008) 0.75
Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis. CNS Drugs (2015) 0.75
Cost-benefit analysis of hospital based postpartum vaccination with combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap). Vaccine (2013) 0.75
Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials. Expert Rev Pharmacoecon Outcomes Res (2014) 0.75
A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments. Pharmacoeconomics (2014) 0.75
Factors Associated with Failure to Achieve SVR in Hepatitis C Genotype 3 Patients Within an Integrated Care Delivery System. J Manag Care Spec Pharm (2015) 0.75
Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy. J Med Econ (2013) 0.75